CN102947271A - 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]-3-氟苯氧基}-n-甲基吡啶-2-羧酰胺、其盐和一水合物的方法 - Google Patents
制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]-3-氟苯氧基}-n-甲基吡啶-2-羧酰胺、其盐和一水合物的方法 Download PDFInfo
- Publication number
- CN102947271A CN102947271A CN2011800191501A CN201180019150A CN102947271A CN 102947271 A CN102947271 A CN 102947271A CN 2011800191501 A CN2011800191501 A CN 2011800191501A CN 201180019150 A CN201180019150 A CN 201180019150A CN 102947271 A CN102947271 A CN 102947271A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- acid
- amino
- monohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
Description
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10004022 | 2010-04-15 | ||
EP10004022.9 | 2010-04-15 | ||
PCT/EP2011/055508 WO2011128261A1 (en) | 2010-04-15 | 2011-04-08 | Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410248545.4A Division CN103980191A (zh) | 2010-04-15 | 2011-04-08 | 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]-3-氟苯氧基}-n-甲基吡啶-2-羧酰胺、其盐和一水合物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102947271A true CN102947271A (zh) | 2013-02-27 |
CN102947271B CN102947271B (zh) | 2016-11-09 |
Family
ID=44070712
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410248545.4A Pending CN103980191A (zh) | 2010-04-15 | 2011-04-08 | 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]-3-氟苯氧基}-n-甲基吡啶-2-羧酰胺、其盐和一水合物的方法 |
CN201180019150.1A Active CN102947271B (zh) | 2010-04-15 | 2011-04-08 | 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]-3-氟苯氧基}-n-甲基吡啶-2-羧酰胺、其盐和一水合物的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410248545.4A Pending CN103980191A (zh) | 2010-04-15 | 2011-04-08 | 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]-3-氟苯氧基}-n-甲基吡啶-2-羧酰胺、其盐和一水合物的方法 |
Country Status (39)
Country | Link |
---|---|
US (5) | US8748622B2 (zh) |
EP (1) | EP2558448B1 (zh) |
JP (1) | JP5934182B2 (zh) |
KR (2) | KR20170129276A (zh) |
CN (2) | CN103980191A (zh) |
AR (2) | AR081060A1 (zh) |
AU (1) | AU2011240113B2 (zh) |
BR (1) | BR112012026117B1 (zh) |
CA (1) | CA2796238C (zh) |
CL (1) | CL2012002840A1 (zh) |
CO (1) | CO6630136A2 (zh) |
CR (1) | CR20120526A (zh) |
CU (2) | CU24123B1 (zh) |
DK (1) | DK2558448T3 (zh) |
DO (2) | DOP2012000268A (zh) |
EC (1) | ECSP12012234A (zh) |
ES (1) | ES2542610T3 (zh) |
GT (1) | GT201200280A (zh) |
HK (1) | HK1200831A1 (zh) |
HR (1) | HRP20150885T1 (zh) |
HU (1) | HUE026821T2 (zh) |
IL (2) | IL222348B (zh) |
JO (1) | JO3158B1 (zh) |
MA (1) | MA34156B1 (zh) |
MX (1) | MX2012011734A (zh) |
MY (2) | MY162359A (zh) |
NZ (1) | NZ602997A (zh) |
PE (2) | PE20160838A1 (zh) |
PL (1) | PL2558448T3 (zh) |
PT (1) | PT2558448E (zh) |
RS (1) | RS54219B1 (zh) |
RU (1) | RU2581585C2 (zh) |
SG (2) | SG184172A1 (zh) |
SI (1) | SI2558448T1 (zh) |
TN (1) | TN2012000492A1 (zh) |
TW (2) | TWI539951B (zh) |
UA (1) | UA110613C2 (zh) |
UY (2) | UY33290A (zh) |
WO (1) | WO2011128261A1 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104250227A (zh) * | 2013-06-29 | 2014-12-31 | 广东东阳光药业有限公司 | 瑞戈非尼新晶型及其制备方法 |
CN104557689A (zh) * | 2015-01-26 | 2015-04-29 | 重庆两江药物研发中心有限公司 | 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法 |
CN104592105A (zh) * | 2015-02-10 | 2015-05-06 | 杭州朱养心药业有限公司 | 瑞戈非尼及其制法 |
CN105218439A (zh) * | 2014-06-06 | 2016-01-06 | 连云港润众制药有限公司 | 一种瑞格非尼的晶体及其制备方法 |
CN105330600A (zh) * | 2015-11-30 | 2016-02-17 | 山东罗欣药业集团股份有限公司 | 一种瑞戈菲尼的制备方法 |
CN105879049A (zh) * | 2016-05-13 | 2016-08-24 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
CN107118153A (zh) * | 2016-02-25 | 2017-09-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种瑞戈非尼一水合物晶型及其制备方法 |
CN109438337A (zh) * | 2018-11-27 | 2019-03-08 | 广东安诺药业股份有限公司 | 一种瑞戈非尼中间体的制备工艺 |
CN109438336A (zh) * | 2018-11-27 | 2019-03-08 | 广东安诺药业股份有限公司 | 一种瑞戈非尼水合物的制备方法 |
CN114315710A (zh) * | 2022-01-07 | 2022-04-12 | 江苏豪森药业集团有限公司 | 一种制备或纯化瑞戈非尼的方法 |
CN114315710B (zh) * | 2022-01-07 | 2024-04-26 | 江苏豪森药业集团有限公司 | 一种制备或纯化瑞戈非尼的方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877933B2 (en) * | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JO3479B1 (ar) * | 2012-09-06 | 2020-07-05 | Bayer Healthcare Llc | تركيبة دوائية مغلفة تحتوي على ريجورافنيب |
PT2900269T (pt) | 2012-09-25 | 2018-10-22 | Bayer Pharma AG | Combinação de regorafenib e ácido acetilsalicílico para o tratamento de cancro colorretal |
IN2013CH04511A (zh) * | 2013-10-04 | 2015-04-10 | Hetero Research Foundation | |
WO2016005874A1 (en) * | 2014-07-09 | 2016-01-14 | Shilpa Medicare Limited | Process for the preparation of regorafenib and its crystalline forms |
SG11201806116SA (en) * | 2016-01-18 | 2018-08-30 | Natco Pharma Ltd | An improved process for the preparation of regorafenib |
AU2018276273B2 (en) | 2017-06-02 | 2023-12-21 | Bayer Healthcare Llc | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer |
EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
WO2021160708A1 (en) | 2020-02-14 | 2021-08-19 | Bayer Aktiengesellschaft | Combination of regorafenib and msln-ttc for treating cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1856469A (zh) * | 2003-07-23 | 2006-11-01 | 拜尔医药品股份有限公司 | 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲 |
CN101547903A (zh) * | 2006-10-11 | 2009-09-30 | 拜耳先灵制药股份公司 | 4-[4-({[4-氯-3-(三氟甲基)苯基)]氨基甲酰基}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺一水合物 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20080269265A1 (en) | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
IL144144A0 (en) | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
MXPA04005137A (es) | 2001-12-03 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuestos de aril urea en combinacion con otros agentes citostaticos para el tratamiento de canceres humanos. |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
JP4527401B2 (ja) | 2002-02-11 | 2010-08-18 | バイエル、ファーマシューテイカルズ、コーポレイション | キナーゼ阻害剤としてのアリール尿素 |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
JP4636486B2 (ja) | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | 脈管形成阻害活性を有するアリール尿素 |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
ES2305808T3 (es) | 2003-05-20 | 2008-11-01 | Bayer Healthcare Llc | Diarilureas con actividad inhibidora de quinasas. |
MXPA06012394A (es) | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer. |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
MX2007002398A (es) | 2004-08-27 | 2007-05-15 | Bayer Pharmaceuticals Corp | Nuevas composiciones farmaceuticas para el tratamiento de cancer. |
US8877933B2 (en) | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
UA90691C2 (en) | 2004-09-29 | 2010-05-25 | Баер Шеринг Фарма Акциенгезельшафт | Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide |
WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
CA2627873A1 (en) | 2005-10-31 | 2007-05-10 | Scott Wilhelm | Treatment of cancer with sorafenib |
WO2007059154A2 (en) | 2005-11-14 | 2007-05-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
WO2008055629A1 (en) * | 2006-11-09 | 2008-05-15 | Bayer Schering Pharma Aktiengesellschaft | Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
WO2008058644A1 (en) * | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
US8101773B2 (en) | 2006-12-20 | 2012-01-24 | Bayer Healthcare Llc | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer |
CA2675980C (en) | 2007-01-19 | 2016-06-21 | Bayer Healthcare Llc | Use of dast for treatment of cancers with acquired resistance to kit inhibitors |
JP2010516692A (ja) | 2007-01-19 | 2010-05-20 | バイエル・ヘルスケア・エルエルシー | 化学療法剤に対し抵抗性を有する癌の処置 |
EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
US20110257035A1 (en) | 2008-10-21 | 2011-10-20 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
AU2010247397B2 (en) | 2009-05-15 | 2012-07-12 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2013531067A (ja) | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
KR20130099117A (ko) | 2010-10-01 | 2013-09-05 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 치환된 n-(2-아릴아미노)아릴 설폰아미드 함유 배합물 |
CA2840491A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sorafenib |
PE20141031A1 (es) | 2011-06-28 | 2014-08-21 | Bayer Healthcare Llc | Composicion farmaceutica oftalmologica topica que contiene regorafenib |
US8841500B2 (en) | 2011-11-08 | 2014-09-23 | Chevron U.S.A. Inc. | Preparation of alkyl aromatic compounds |
JP2014032346A (ja) | 2012-08-06 | 2014-02-20 | Japan Display Inc | 液晶表示パネル |
JO3479B1 (ar) | 2012-09-06 | 2020-07-05 | Bayer Healthcare Llc | تركيبة دوائية مغلفة تحتوي على ريجورافنيب |
-
2011
- 2011-03-23 AR ARP110100982A patent/AR081060A1/es not_active Application Discontinuation
- 2011-03-24 UY UY0001033290A patent/UY33290A/es active IP Right Grant
- 2011-04-08 CN CN201410248545.4A patent/CN103980191A/zh active Pending
- 2011-04-08 PE PE2016000780A patent/PE20160838A1/es unknown
- 2011-04-08 NZ NZ602997A patent/NZ602997A/en unknown
- 2011-04-08 SG SG2012069852A patent/SG184172A1/en unknown
- 2011-04-08 KR KR1020177032906A patent/KR20170129276A/ko not_active Application Discontinuation
- 2011-04-08 EP EP20110712881 patent/EP2558448B1/en active Active
- 2011-04-08 BR BR112012026117-7A patent/BR112012026117B1/pt active IP Right Grant
- 2011-04-08 PE PE2012002008A patent/PE20130181A1/es active IP Right Grant
- 2011-04-08 US US13/640,959 patent/US8748622B2/en active Active
- 2011-04-08 JP JP2013504206A patent/JP5934182B2/ja active Active
- 2011-04-08 SI SI201130559T patent/SI2558448T1/sl unknown
- 2011-04-08 PL PL11712881T patent/PL2558448T3/pl unknown
- 2011-04-08 PT PT117128819T patent/PT2558448E/pt unknown
- 2011-04-08 HU HUE11712881A patent/HUE026821T2/en unknown
- 2011-04-08 DK DK11712881.9T patent/DK2558448T3/en active
- 2011-04-08 CN CN201180019150.1A patent/CN102947271B/zh active Active
- 2011-04-08 MY MYPI2012004548A patent/MY162359A/en unknown
- 2011-04-08 RS RS20150528A patent/RS54219B1/en unknown
- 2011-04-08 MX MX2012011734A patent/MX2012011734A/es active IP Right Grant
- 2011-04-08 MY MYPI2016001879A patent/MY177066A/en unknown
- 2011-04-08 CU CU20120147A patent/CU24123B1/es active IP Right Grant
- 2011-04-08 WO PCT/EP2011/055508 patent/WO2011128261A1/en active Application Filing
- 2011-04-08 CA CA2796238A patent/CA2796238C/en active Active
- 2011-04-08 RU RU2012148386/04A patent/RU2581585C2/ru active
- 2011-04-08 SG SG10201501221UA patent/SG10201501221UA/en unknown
- 2011-04-08 KR KR1020127026728A patent/KR101800041B1/ko active IP Right Grant
- 2011-04-08 ES ES11712881.9T patent/ES2542610T3/es active Active
- 2011-04-08 MA MA35304A patent/MA34156B1/fr unknown
- 2011-04-08 AU AU2011240113A patent/AU2011240113B2/en active Active
- 2011-04-13 JO JOP/2011/0125A patent/JO3158B1/ar active
- 2011-04-14 TW TW103141317A patent/TWI539951B/zh active
- 2011-04-14 TW TW100112905A patent/TWI475992B/zh active
- 2011-08-04 UA UAA201212983A patent/UA110613C2/uk unknown
-
2012
- 2012-10-08 EC ECSP12012234 patent/ECSP12012234A/es unknown
- 2012-10-10 CL CL2012002840A patent/CL2012002840A1/es unknown
- 2012-10-11 IL IL222348A patent/IL222348B/en active IP Right Grant
- 2012-10-11 GT GT201200280A patent/GT201200280A/es unknown
- 2012-10-12 CO CO12180992A patent/CO6630136A2/es not_active Application Discontinuation
- 2012-10-12 TN TNP2012000492A patent/TN2012000492A1/en unknown
- 2012-10-12 DO DO2012000268A patent/DOP2012000268A/es unknown
- 2012-10-16 CR CR20120526A patent/CR20120526A/es unknown
-
2014
- 2014-04-15 US US14/252,850 patent/US9458107B2/en active Active
- 2014-05-26 CU CU2014000060A patent/CU20140060A7/es unknown
-
2015
- 2015-02-10 HK HK15101433.6A patent/HK1200831A1/zh unknown
- 2015-08-19 HR HRP20150885TT patent/HRP20150885T1/hr unknown
-
2016
- 2016-09-08 US US15/259,576 patent/US20170057918A1/en not_active Abandoned
- 2016-10-20 DO DO2016000285A patent/DOP2016000285A/es unknown
-
2017
- 2017-06-22 IL IL253119A patent/IL253119B/en active IP Right Grant
- 2017-08-03 US US15/668,178 patent/US20170334857A1/en not_active Abandoned
-
2019
- 2019-01-09 US US16/243,284 patent/US10822305B2/en active Active
- 2019-09-13 AR ARP190102596A patent/AR116395A2/es unknown
-
2021
- 2021-12-23 UY UY0001039590A patent/UY39590A/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1856469A (zh) * | 2003-07-23 | 2006-11-01 | 拜尔医药品股份有限公司 | 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲 |
CN101547903A (zh) * | 2006-10-11 | 2009-09-30 | 拜耳先灵制药股份公司 | 4-[4-({[4-氯-3-(三氟甲基)苯基)]氨基甲酰基}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺一水合物 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104250227A (zh) * | 2013-06-29 | 2014-12-31 | 广东东阳光药业有限公司 | 瑞戈非尼新晶型及其制备方法 |
CN105218439B (zh) * | 2014-06-06 | 2018-11-20 | 连云港润众制药有限公司 | 一种瑞格非尼的晶体及其制备方法 |
CN105218439A (zh) * | 2014-06-06 | 2016-01-06 | 连云港润众制药有限公司 | 一种瑞格非尼的晶体及其制备方法 |
CN104557689A (zh) * | 2015-01-26 | 2015-04-29 | 重庆两江药物研发中心有限公司 | 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法 |
CN104592105A (zh) * | 2015-02-10 | 2015-05-06 | 杭州朱养心药业有限公司 | 瑞戈非尼及其制法 |
CN105330600A (zh) * | 2015-11-30 | 2016-02-17 | 山东罗欣药业集团股份有限公司 | 一种瑞戈菲尼的制备方法 |
CN105330600B (zh) * | 2015-11-30 | 2018-05-22 | 山东罗欣药业集团股份有限公司 | 一种瑞戈菲尼的制备方法 |
CN107118153A (zh) * | 2016-02-25 | 2017-09-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种瑞戈非尼一水合物晶型及其制备方法 |
CN105879049A (zh) * | 2016-05-13 | 2016-08-24 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
CN109438337A (zh) * | 2018-11-27 | 2019-03-08 | 广东安诺药业股份有限公司 | 一种瑞戈非尼中间体的制备工艺 |
CN109438336A (zh) * | 2018-11-27 | 2019-03-08 | 广东安诺药业股份有限公司 | 一种瑞戈非尼水合物的制备方法 |
CN109438337B (zh) * | 2018-11-27 | 2019-08-09 | 广东安诺药业股份有限公司 | 一种瑞戈非尼中间体的制备工艺 |
CN109438336B (zh) * | 2018-11-27 | 2019-11-22 | 广东安诺药业股份有限公司 | 一种瑞戈非尼水合物的制备方法 |
CN114315710A (zh) * | 2022-01-07 | 2022-04-12 | 江苏豪森药业集团有限公司 | 一种制备或纯化瑞戈非尼的方法 |
CN114315710B (zh) * | 2022-01-07 | 2024-04-26 | 江苏豪森药业集团有限公司 | 一种制备或纯化瑞戈非尼的方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102947271A (zh) | 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]-3-氟苯氧基}-n-甲基吡啶-2-羧酰胺、其盐和一水合物的方法 | |
TWI651305B (zh) | 製備pde4抑制劑之方法 | |
CN106187882A (zh) | 制备化合物的方法及其合成中间体 | |
CN108623567A (zh) | 奥斯替尼的制备方法 | |
JP2022515070A (ja) | アミド誘導体の不純物及びその使用 | |
CN104402863A (zh) | 一锅法制备泊马度胺 | |
KR100990046B1 (ko) | 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법 | |
CN109574860B (zh) | 一种制备维兰特罗的方法 | |
CN111892544A (zh) | 一种3-(氨基甲基)-4-(4-氟苯基)哌嗪-1-羧酸叔丁酯及其合成方法 | |
JP2018090551A (ja) | L−カルノシン誘導体またはその塩、及びl−カルノシンまたはその塩の製造方法 | |
CN106008323B (zh) | 一种制备哌马色林半酒石酸盐晶型c的方法 | |
AU2015201426B2 (en) | Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate | |
CN114195684B (zh) | 一种氨基保护基n-取代手性氨基酸的合成方法 | |
US6593475B1 (en) | Preparation of derivative of 3-sulfonamido-4-phenylaminopyridine | |
CN102791692B (zh) | 叔丁氧基羰基胺化合物的制造方法 | |
CN116478160A (zh) | 恶唑酮类苦参碱衍生物及其制备方法与应用 | |
CN111100111A (zh) | 一种制备苯并噻吩衍生物的方法 | |
CN108191686A (zh) | 亚氨基二乙酸二叔丁酯的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1181379 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BAYER CORP. Free format text: FORMER OWNER: BAYER INTELLECTUAL PROPERTY GMBH Effective date: 20140108 Owner name: BAYER INTELLECTUAL PROPERTY GMBH Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG Effective date: 20140108 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140108 Address after: American New York Applicant after: BAYER HEALTHCARE LLC Address before: German Monheim Applicant before: BAYER INTELLECTUAL PROPERTY GmbH Effective date of registration: 20140108 Address after: German Monheim Applicant after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Berlin Applicant before: BAYER PHARMA AG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1181379 Country of ref document: HK |